Tilray Inc. ($TLRY) Stock Forecast: Down 5.1% Today

What is Tilray Inc.?

Tilray Brands (NASDAQ: TLRY) operates in various markets, including Canada, international medical cannabis, and the US. The stock experienced bearish movement today.

Why is Tilray Inc. going down?

TLRY stock is down 5.1% on Jan 16, 2026 15:45

• Tilray's shares declined by 1.9% today, staying close to its 50-day moving average and below its 200-day average, indicating a bearish sentiment in the market.
• The company failed to meet quarterly EPS estimates and revealed negative net margins, resulting in a downgrade to a "strong sell" rating by Zacks Research.
• Despite achieving record Q2 revenues from international operations, Tilray's stock currently holds a Zacks Rank #5 (Strong Sell) primarily due to concerns about its US market prospects.
• Analysts have a cautious stance on Tilray's stock, advising investors to consider other investment opportunities in light of the company's financial performance and market outlook.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Tilray Brands (NASDAQ:TLRY) Shares Down 1.9% - What's Next?

Tilray Brands (NASDAQ:TLRY) shares fell 1.9% during mid-day trading to $9.71, with trading volume down 41% compared to the average session. The stock currently hovers near its 50-day moving average and below its 200-day average, holding a "Reduce" consensus rating and a $15 target price from analysts. Tilray missed quarterly EPS estimates at ($0.41) against an expected ($0.14) but exceeded revenue expectations with $217.5 million, displaying significant negative net margins and return on equity.

https://www.marketbeat.com/instant-alerts/tilray-brands-nasdaqtlry-shares-down-19-whats-next-2026-01-15/

Tilray Continues to Gain in Canada and International Medical, but We're Skeptical of US Prospects

Morningstar maintains a skeptical outlook on Tilray's U.S. market prospects despite its continued growth in Canada and the international medical cannabis sector. The report highlights analyst notes on Tilray's decent earnings and recent cannabis rescheduling news, while the company focuses on cultivating cannabis in Canada, exporting internationally, and selling CBD and alcohol.

https://www.morningstar.com/company-reports/1417598-tilray-continues-to-gain-in-canada-and-international-medical-but-were-skeptical-of-us-prospects

Tilray Brands (NASDAQ:TLRY) Downgraded to "Strong Sell" Rating by Zacks Research

Zacks Research has downgraded Tilray Brands (NASDAQ:TLRY) from a "hold" to a "strong sell" rating. The company reported a quarterly loss missing analyst estimates and has a consensus target price of $15.00 with mixed sell-side coverage including one Buy, four Hold, and two Sell ratings. Institutional ownership of the stock is currently 9.35%.

https://www.marketbeat.com/instant-alerts/tilray-brands-nasdaqtlry-downgraded-to-strong-sell-rating-by-zacks-research-2026-01-15/

What's Next for Tilray Brands After Posting Record Q2 Revenues?

Tilray Brands (TLRY) reported record Q2 fiscal 2026 revenues of $217.5 million, marking a 3% year-over-year increase, primarily driven by strong international operations and its Distribution business. The company is strategically shifting focus to higher-margin international cannabis markets and expects improvements in its Beverage business by Q4. Tilray's stock has seen a significant surge recently, but it currently holds a Zacks Rank #5 (Strong Sell).

https://www.theglobeandmail.com/investing/markets/stocks/CGC/pressreleases/37039759/whats-next-for-tilray-brands-after-posting-record-q2-revenues/

Tilray Brands (NASDAQ:TLRY) Shares Up 1.3% - Still a Buy?

Tilray Brands (NASDAQ:TLRY) shares increased by 1.3% during mid-day trading but analysts maintain a "Hold" rating with a target price of $20.00. The company recently reported a significant EPS miss with ($0.41) against estimates of ($0.14) and deeply negative net margins. Despite some institutional investors increasing their positions, analysts suggest considering other stocks for better investment opportunities.

https://www.marketbeat.com/instant-alerts/tilray-brands-nasdaqtlry-shares-up-13-still-a-buy-2026-01-12/

Trending Today

Bittensor ($TAO) Crypto Forecast: Up 5.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 16.9% Today

Halliburton Company ($HAL) Stock Forecast: Up 5.1% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 6.8% Today

Citizens Financial Group Inc. ($CFG) Stock Forecast: Up 6.8% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.3% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 18.5% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 20.0% Today

Power Integrations Inc. ($POWI) Stock Forecast: Up 5.9% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Up 5.7% Today

Tilray Inc. Price History

13.00.2026 - TLRY Stock was down 5.3%

• Despite achieving record revenue and moving to a net cash position, Tilray's stock witnessed a notable bearish trend.
• The market reaction may have been influenced by a substantial EPS miss and deeply negative net margins, sparking investor concerns.
• Analysts recommending exploring alternative investment options despite increased positions from certain institutional investors might have exacerbated the bearish outlook.
• Ongoing worries surrounding operating losses, potential shareholder dilution, and the necessity for Tilray to capitalize on emerging market trends to enhance margins and cash flow likely played a role in the stock's bearish performance.

22.11.2025 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today could be attributed to the company's ongoing financial struggles, lack of earnings, and cash burn.
• Despite recent positive sentiment and stock rises driven by potential easing of marijuana restrictions and strategic developments, the market may be reacting to the underlying financial challenges faced by Tilray.
• The uncertainty surrounding U.S. marijuana reform, particularly the reliance on federal rescheduling rather than outright legalization, might be causing investors to exercise caution and reevaluate their positions in Tilray.

22.11.2025 - TLRY Stock was down 6.0%

• The bearish movement in TLRY stock today could be attributed to the anticipation and uncertainty surrounding the upcoming financial results announcement.
• Comments on Tilray's lack of earnings may have contributed to investor skepticism and selling pressure on the stock.
• Despite the positive news about Tilray's formation of Tilray Medical USA, Inc. to advance its U.S. medical cannabis operations, the overall market sentiment may have been overshadowed by concerns about the company's financial performance and growth strategy.
• The market might be reacting to the realization that Tilray's growth is primarily driven by acquisitions in the alcohol sector rather than its struggling cannabis segment, raising doubts about the company's long-term sustainability.

19.11.2025 - TLRY Stock was down 8.4%

• There was a significant bearish movement in TLRY stock today, possibly due to investors cashing out profits following a recent surge triggered by indications of potential marijuana reclassification by a former President.
• Market reaction may be influenced by experts warning that moving cannabis to Schedule III doesn't mean federal legalization, causing uncertainty and prompting selling.
• Despite forming Tilray Medical USA, Inc. to expand U.S. medical cannabis operations, the company's financial difficulties, ongoing losses, and focus on alcohol acquisitions rather than cannabis growth could be fueling negative market sentiment.
• The uncertain regulatory landscape for cannabis, paired with a recent reverse split and general market instability, may be intensifying downward pressure on Tilray's stock price.

12.00.2026 - TLRY Stock was up 4.9%

• Reported a record Q2 Fiscal 2026 net revenue of $218 million, led by strong performance in international cannabis and Canadian adult-use cannabis segments.
• Transitioned to a net cash position and reaffirmed full-year Adjusted EBITDA guidance, highlighting disciplined execution and a strengthened balance sheet.
• Analysts' opinion that the recent share plunge was overdone aligns with financial results, suggesting potential undervaluation due to underestimation of profit growth in Canadian and international cannabis markets.
• Strategic expansion into the beverage segment, along with readiness to leverage medical cannabis infrastructure in the U.S., positions the company for future growth amidst potential regulatory shifts in the cannabis market.

16.00.2026 - TLRY Stock was down 5.1%

• Tilray's shares declined by 1.9% today, staying close to its 50-day moving average and below its 200-day average, indicating a bearish sentiment in the market.
• The company failed to meet quarterly EPS estimates and revealed negative net margins, resulting in a downgrade to a "strong sell" rating by Zacks Research.
• Despite achieving record Q2 revenues from international operations, Tilray's stock currently holds a Zacks Rank #5 (Strong Sell) primarily due to concerns about its US market prospects.
• Analysts have a cautious stance on Tilray's stock, advising investors to consider other investment opportunities in light of the company's financial performance and market outlook.

15.00.2026 - TLRY Stock was up 5.3%

• Tilray reported record Q2 revenues of $218 million, driven by international operations and distribution, showcasing the company's ability to capture market opportunities.
• Despite a recent EPS miss and negative net margins, the stock saw an increase as investors may be optimistic about the company's long-term growth prospects.
• The focus on higher-margin international markets and new THC beverage offerings indicates Tilray's commitment to diversification and sustainable profitability, which could have positively influenced investor sentiment.
• Analysts suggesting to consider other stocks for better investment opportunities may have created some uncertainty, but the overall market movement reflects confidence in Tilray's strategic direction and potential for future growth.

24.11.2025 - TLRY Stock was down 5.3%

• The upcoming announcement of Tilray Brands' second fiscal quarter financial results has likely created uncertainty and caution among investors, leading to a sell-off of the stock.
• Despite the recent drop, the stock has shown a notable increase over the past month, indicating potential profit-taking by traders.
• The lack of substantial analysis suggests a disconnect between market sentiment and speculative opinions on whether the stock's fall presents a buying opportunity.
• Investors are eagerly awaiting the earnings report, with expectations of a significant increase in EPS, but a slight decrease in revenue compared to the previous year, adding to the volatility surrounding the stock.

06.00.2026 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today can be attributed to multiple factors:
• The formation of a bearish head-and-shoulders pattern, indicating a potential trend reversal and investor caution.
• Heightened volatility ahead of the earnings release, with analysts expecting significant price swings and a projected loss per share.
• The company's expansion into non-alcoholic, cannabis-infused beverages for its "Dry January" campaign might not have been well-received by investors, impacting the stock negatively.
• Investors are closely monitoring Tilray's financial results release on January 9th, potential cannabis reclassification efforts in the US, and the impact of increased competition in the US market for further insights into the stock's performance.

02.00.2026 - TLRY Stock was up 5.6%

• Tilray's stock is struggling to maintain momentum despite recent U.S. regulatory shifts and political support, trading below key technical levels.
• Investor focus is on the upcoming Q2 earnings report, with expectations of a loss per share on revenue. Analysts are looking for signs of financial progress from cost-saving measures and brand integrations.
• The stock's increased attention on social media platforms is sparking discussions about whether TLRY's current mid-single digit trading price reflects a genuine recovery or speculative hype.
• Analysts have a cautiously optimistic stance, considering potential U.S. policy changes and growth in Tilray's alcohol business, balanced against risks like weak cannabis sales and ongoing losses.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock price decreased by 4.2%, closing at $10.085, which was below the broader market performance.
• Analysts have given a consensus "Hold" rating with an average price target of $20, showing caution among investors.
• The drop in stock price may be linked to lower-than-expected performance and uncertainties about the upcoming second fiscal quarter results.
• Despite optimistic prospects for potential cannabis rescheduling and hemp-derived products, investors might be hesitant due to recent underperformance and competition in the AI sector.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock experienced a 4.2% decline in value during mid-day trading, closing at $10.085.
• Analysts have assigned a consensus "Hold" rating to Tilray, with a median price target of $20, indicating a potential upside of 88.49%.
• The bearish movement could be attributed to the cautious sentiment among analysts, despite potential positive developments such as cannabis rescheduling and revised product definitions.
• The upcoming announcement of Tilray's second fiscal quarter results may also be contributing to investor uncertainty and selling pressure on the stock.